Multistage epidermal carcinogenesis in transgenic mice: Cooperativity and paradox

Journal of Investigative Dermatology Symposium Proceedings

Volumn 1, Issue 2, 1996, Pages 162-176

  Greenhalgh, David A ^a   Wang, Xiao Jing ^a   Roop, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Fos; Keratin vectors; P53; Rasha; Tgf

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL; HUMAN; MOUSE; ONCOGENE; ONCOGENE RAS; PHYSIOLOGY; REVIEW; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; GENES, FOS; GENES, P53; GENES, RAS; HUMANS; MICE; MICE, TRANSGENIC; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0030112254     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. Cairns , J: Mutation selection and the natural history of cancer. Nature 255:197-200, 1975
2. Bishop J, M: Molecular Themes in Oncogenesis. Crll 64:235-2-48, 1991
3. Knudson A, G: Genetics of human cancer. Adv Cancer Res 20:231-251, 1986
4. Weinberg R, A: Oncogenes, Antioncogenes and the molecular basis of multistep carcinogenesis. Cancer Res 49:3713-3721, 1989
5. Renan , M: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139-146, 1993
6. Fearon ER, Jones P, A: Progressing toward a molecular description of colorectal cancer development. FASEDJ 6:2783-2790, 1992
7. Marshall C, J: Tumor suppressor genes. Cell 64:313-326, 1991
8. Hunter , T: Cooperation between oncogenes. Cell 64:249-270, 1991
9. Hunter T, Pines , J: Cyclins and cancer I, I: Cyclin D and CDK inhibitors come of age. Cell 79:573-550, 1994
10. Hanahan , D: Dissecting multistep tumorigenesis in transgenic mice. Ann Rev Genet 22:479-519, 1988
11. Sinn E, Muller W, Pattengale P, Tapler I, Wallace R, Leder , P: Co-expression of mouse v-Ha-ras and MMTV/c-myc genes in transgenic mice; synergistic action of oncogenes in vivo. Cell 49:415- 475, 1987
12. Yuspa SH, Pouirier M, C: Chemical carcinogenesis; from animal models to molecular models in one decade. Adv Cancer Res 50:25-70, 1988
13. Balmain A, Brown , K: Oncogene activation in chemical carcinogenesis. Adv Cancer Res 51:147-182, 1988
14. Hennings H, Shores R, Wenk ML, Spangler LF, Tarone R, Yuspa S, H: Malignant conversion of mouse skin tumors is increased by tumor initiators and unaffected by tumor promoters. Nature 304:67-69, 1983
15. Glass AG, Hoover R, N: The emerging epidermic of melanoma and squamous cell skin cancer. JAMA 262:2097-2100, 1989
16. Kelfkeng G, de Gruijl FR, van der Leun J, C: Ozone depletion and increase in annual carcinogenic ultra-violet dose. Photctchem Plwtobiol 52:819-831, 1990
17. Regan J, D: So who goes sunbathing in Antartica? N1H Res 3:52-54, 1991
18. Anderson W, F: Human gene therapy. Science 256:808-812, 1992
19. Greenhalgh DA, Rothnagel JA, Quintanilla Ml, Orengo C, Gagne TA, Bundman DS, Longley MA, Roop D, R: Induction of epidermal hyperplasia, hyperkeratosis and papillomas in transgenic mice by a targeted v-Ha-ras oncogene. AW Carcinog 7:99-110, 1993
20. Greenhalgh DA, Rothnagel JA, Wang X-J, Quintanilla MI, Orengo CC, Gagne TA, Bundman DS, Longley MA, Fisher C, Roop D, R: Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggests a role for fos in epidermal differentiation and neoplasia. 0,108:2145-2157,1993
21. Dominey AM, Wang X-J, King LE, Jr. Nanney LE, Gagne TA, Sellheyer K, Bundman DS, Longley MA, Rothnagel JA, Greenhalgh DA, Roop D, R: Targeted overexpression of transforming growth factor-a in the epidermis of transgenic mice eb'cits hyperplasia, hyperkeratosis and spontaneous squamous papillomas. Cell Grou-th and Dif4:1071-1082, 1993
22. Ha activated papillomas. Cell Growth and Diff 5:667-675, 1993
23. Greenhalgh DA, Quintanilla MI, Orengo CC, Barber JL, Eckhardt JN, Rothnagel JA, Roop D, R: Cooperation between v-fos and v-rasH" induces autonomous papillomas in transgenic epidermis but not malignant conversion. Cancer Re! 53:5071-5075, 1993
24. Wang X-J, Greenhalgh DA, Eckhardt JN, Rothnagel JA, Roop D, R: Epidermal expression of TGFot in transgenic mice elicits spontaneous and TPA induced papillomas via a mechanism independent of mi"4 activation or overexpressïon. Mol Carcinog 10:15-22, 1994
25. Wang XJ, Greenhalgh DA, Bickenbach JR, Roop D, R: TGFa and v-fos cooperation in transgenic mouse epidermis induces aberant differentiation and stable autonomous papillomas. Oncogene 10:219-289, 1995
26. Steinen PM, Roop D, R: Molecular and cell biology of intermediate filaments. Anna Rev Biocliem 57:593-625, 1988
27. Bailleul B. Surani MA, White S, Barton SC, Brown K, Blessing M, Jorcano J, Balmain , A: Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. Cell 62:697708, 1990
28. Vassar R, Fuchs , E: Transgenic mice provide new insights into the role of TGFor during epidermal development and differentiation. Genes & Dev 5:714-727, 1991
29. Timely JM, Fisher C, Searle P, F: Abnormalities of epidermal differentiation associated with expression of the human papillomavirus type 1 early region in transgenic mice. J Ccn Viml 73:1251-1260, 1992
30. Auewarakul P, Gissmein L, Cid-Arregui , A: Targeted epidermal expression of the E6 and E7 oncogenes of Human Papillomavirus Type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Bial 14:8250-8258, 1994
31. Chung SY, Cheng CK, Rothnagel JA, Yu SH, Nakazawa H, Mehrel T, Hohl D, Rosenthal DS, Steinen PM, Yuspa SH, Roop D, R: Expression of human keratin gene (Kl) in transgenic mice is tissue and developmental-specific but altered with respect to differentiation state. Mol Cell Di/2:61-81, 1994
32. Rosenthal DS, Steinen PM, Chung C, Huff CA, Yuspa SH, Roop D, R: A human epidermal differentiation specific keratin gene is regulated by calcium but not negative modulators of differentiation in transgenic mouse keratinocytes. Cell Grouth ami Dig 2:107-113, 1991
33. Barbacid , M: Ras genes. Anna Rev Biocliem 56:779-827, 1986
34. Bos J, L: The ras gene family and human carcinogenesis. Mutant Res 198:255271, 1988
35. Lowy DR. Willumsen B, M: Function and regulation of Ras. Anna Rev Biochtm 62:851-871, 1993
36. Margolis B, Schlessinger , J: Guanine-nucleotide-releasing factor hSosl binds to Grb2 and links receptor tyrosine klnases to Ras signalling. Nature 363:15-16, 1993
37. Buday L, Downward , J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73:611-620, 1993
38. Suen KL, Bustelo XR, Pawson T, Barbacid , M: Molecular cloning of the mouse grb2 gene: differential interaction of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors. Mol Cell Biol 132:55005512, 1993
39. Lang-Caner CA, Plenman CM, Gardner AM, Blumer KJ, Johnson G, L: A divergence in the MAP kinase regulatory network denned by MEK Kinase and RAF. Science 260:315-319, 1993
40. Leevers SJ, Paterson HF, Marshall C, J: Requirement for Ras in Raf activation is overcome by targeting Pvaf to the plasma membrane. Nature 369:411-414, 1994
41. Hall , A: A biochemical function for Ras-at last. Science 264:1413-1414, 1994
42. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi , D: Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 363:88-92, 1993
43. Bollag G, McCormick , F: GTPase activating proteins. Sem Cancer Biol 3:199208, 1992
44. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy , H: H-Ras gene mutations and amplification in human nonmelanoma skin cancers. Mol Carcinog 4:196-202, 1991 .
45. Yuspa SH, Kilkenny AE, Stanley J, Lichti , U: Keratinocytes blocked in phorbol ester responsive early stage of terminal differentiation by Sarcoma viruses. Nature 314:459-462, 1985
46. Quintanilla M, Brown K, Ramsden M, Balmain , A: Carcinogen specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322:78-80, 1986
47. Brown K, Buchannan A, Balmain , A: Carcinogen induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 87:538-542, 1990
48. Nelson MA, Futscher BW, Kinsella T, Wymer J, Bowden G, T: Detection of mutant Ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors. Proc Nail Acad Sci USA 89:6398-6402, 1992
49. Roop DR, Lowy DR. Tamborin PE, Stickland JE, Harper JR, Balaschak M, Spangler EG, Yuspa S, H: An activated Harvey ras oncogene produces benign tumors on mouse epidermal tissue. Nature 323:822-824, 1986
50. Furstenberger G, Rogers M, Schnapke R, Bauer G, Hofler P, Marks , F: Simulatory role of transforming growth factors in multistage skin carcinogens: possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin. IntJ Cancer 43:915-921. 1989
51. Brown K, Quintanilla M, Ramsden M, Kerr IB, Young S, Balmain A: v-ras genes from Harvey and BALD murine sarcoma viruses can act as initiators of two stage mouse skin carcinogenesis. Cell 46:447-456, 1986
52. Bums PA, Kemp CJ, Cannon JV, Lane DP, Bremner R, Balniain , A: Loss of heterozygosity and mutational alterations of the p53 gene in skin tumors of interspecific hybrid mice. Ottcogent 6:2363-2369, 1990
53. Ruggeri B, Caamano J, Goodrow T, DiRado M, Bianchi A, Trono D, Conti CJ, Klein-Santo AJ, P: Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res 51:6615-6621, 1991
54. Greenhalgh DA, Welty DJ, Stickland JE, Yuspa S, H: Spontaneous Ha-ras gene activation in cultured primary murine kerarinocytes: consequences of Ha-ras gene activation in malignant conversion and malignant progression. Alol Carcinog 2:199-207, 1989
55. Bremner R, Baimain , A: Generic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61:407-417, 1990
56. Bianchi AB, Aldaz CM, Conti C, J: Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors. Proc Natl Acad Sci USA 87:6902-6906, 1990
57. Curran , T: The fos oncogene. In: Reddy EP, Skalka AM, Curran T (eds.). Tlie Ontogent Handbook. Elsevier Science Press, Amsterdam, 1988, pp 307-325
58. Morgan J, Curran , T: Stimulus-transcription coupling in the nervous system: involvement of the inducible protooncogenes fos and jun. Ann Rev Neurosci 14:421-451, 1991
59. Curran T, Franza BR, Jr: Fos and Jun: the API connection. Cell 55:395-397, 1988
60. Smeyne RJ, Vendrell M, Hayward M, Baker SJ, Miao GG, Schilling K, Robertson LM, Curran T, Morgan J, I: Continuous c-fos expression precedes programmed cell death in vivo. Nature 363:166-169, 1993
61. Shyu AB, Greenberg M, Belasco J, E: The Fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes & Dev 3:60-72, 1989
62. Miller AD, Curran T, Verma IM: c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell 36:51-60, 1984
63. Basset-Seguin N, Escot C, Blanchard JM, Kerai C, Verrier B, Mïon H, Guillou J, J: High levels of c-fos proto-oncogene expression in normal human adult skin. J Invest Dermatol 94:418-442, 1990
64. Fisher C, Byers MR, ladarola MJ, Powers E, A: Patterns of epithelial expression of fos protein suggests an important role in the transition from viable to cornified cells during keratinization. Development 111:253-258, 1992
65. Smeyne RJ, Schilling K, Roberton L, Luk D, Oberdick J, Curran T, Morgan JL: fos-LacZ transgenic mice: mapping sites of gene introduction in the central nervous system. Neuron 8:13-23, 1992
66. Dotto GP, Gilman MZ, Marvyama M, Weinberg RA: c-myc and c-fos expression in differentiating mouse primary keratinocytes. EMBOJ 5:28532857, 1986
67. Hayes TE, Kitchen AM, Cochran R, H: Inducible binding of a factor to the c-fos regulatory region. Proc Nail Aead Sci USA 84:1272-1276, 1987
68. Rose-John S, Furstenberger G, Krieg P, Besemfelder E, Rincke G, Marks , F: Differential effects of phorbol esters on c-fos and c-myc and ornithine decarboxylase gene expression in mouse skin in vivo. Carcinogenesis 9:831835, 1988
69. Stacy D\V, Watson T, Kung H, Curran , T: Microinjection of transforming ras proteins induces c-fos expression. Mol Cell Biol 7:523-527, 1987
70. Greenhalgh DA, Yuspa S, H: Malignant conversion of murine squamous papilloma cell lines by transfection with the fos oncogene. Mol Carcinog 1:134143, 1988
71. Greenhalgh DA, Welty DJ, Player A, Yuspa S, H: Two oncogenes v-fos and v-ras cooperate to convert noral keratinocytes to squamous cell carcinoma. Proc Natl Acad Sci USA 87:643-647, 1990
72. Miller AD, Verma IM, Curran , T: Deletion of the gag region from FBR murine osteosarcoma virus does not effect its enhanced transforming activity. J Virol 55:521-526, 1985
73. Mischt R, Roop DR, Mehrel T, Yuspa SH, Rentrop M, Winter H, Schweizer , J: Aberant expression during two stage mouse skin carcinogenesis of a type 1 47-kDa keratin, K13, normally associated with terminal differentiation of internal stratified epithelia. Mol Caninog 1:96-108, 1988
74. Roop DR, Krieg TM, Mehrel T, Cheng CK, Yuspa S, H: Transcriptional control of high molecular weight keratin gene expression in multistage mouse skin carcinogenesis. Cancer Res 48:3245-3252, 1988
75. Johnson RS, Spiegelman BM, Papaioannou , V: Pleiotrophic effects of a null mutation in the c-fos protooncogene. Cell 71:577-586, 1992
76. Ruther V, Kontowski D, Schubert FR, Wagner EF: c-fos expression induces bone tumors in transgenic mice. Oncogene 4:861-865, 1989
77. Ha activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy. Cell Growth and Diff 6:579-586
78. Felling JC, Neades R, Strawhecker , J: Epidermal papillomas induced in mouse skin by tumor promoters alone contain a point mutation in the 61st codon of the Ha-ras oncogene. Carcinogenesis 9:665-667, 1988
79. Cross M, Dexter T, M: Growth factors in development, transformation and tumorigenesis. Cell 64:271-280, 1991
80. Elder JT, Fisher GJ, Lindquist PB, Bennelt GL, Pittelkow MR, Coffey RJ, EIHngsworth L, Derynck R, Voorhees J, J: Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 243:811-814, 1989
81. Derynck , R: Transforming growth factor-alpha. Cell 54:593-595, 1988
82. Schreiber AB, Winkler ME, Derynck , R: Transforming growth factor-a: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1252, 1986
83. Imamoto A, Beltran LM, DiGiovanni , J: Evidence for autocrine/paracrine growth stimulation by transforming growth factor-a during the process of skin tumor promotion. Mol Carcinog 4:52-60, 1991
84. Brachman R, Lindquist PB, Nagashima , M: Transmembrane TGFa precursors activate EGF/TGF-a receptors. Cell 56:691-700, 1989
85. Finzi E, Harkins R, Horn , T: TGF-a is widely expressed in differentiated as well as hyperproliferative skin epithelium. J Invest Dcnnatol 96:328-332, 1991
86. Nanny LB, Magid M, Stoscheck CM, King LE, Jr: Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dennatol 83:385-393, 1984
87. Barrandon Y, Green , H: Cell migration is essential for sustained growth of keratinocyte colonies: the roles of transforming growth factor-alpha and epidermal growth factor. Cell 50:1131-1137, 1987
88. Derynck H, Goeddel DV, Ullnich A, GuttermanJU, Williams RD, Bringman IS, Berger W, H: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712, 1987
89. Pittelkow M, Lindquist P, Abraham R, Graves-Deal R, Derynck R, Coffey , R: Induction of transforming growth factor-a expression in human keratinocytes by phorbol esters. J Dial Client 264:5164-5171, 1989
90. Finzi E, Kilkenny A, Strickland JE, Derinck R, Aaronson S, Balaschak M, Bringman T, Yuspa S, H: TGF-a stimulates growth of skin papillomas by autocrine and paracrine mechanisms but does not cause neoplastic progression. Mot Carcinog 1:7-12, 1988
91. Ha oncogene and form papillomas in skin grafts on athymic nude mice. Cancer Res 48:165-170, 1988
92. Click AB, Sporn MB, Yuspa S, H: Altered regulation of TGF beta 1 and TGF alpha in primary keratinocytes and papillomas expressing v-Ha-ras. Mot Carcinog 4:210-219, 1991
93. Jhappan C, Stable C, Harkins RN, Fausto N, Smith GH, Melrino G, T: TGF-a overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61:1137-1146, 1990
94. Sandgren EP, Luetteke NC, Palmitcr RD, Brinster RL, Lee D, C: Overexpression of TGF-a in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia and carcinoma of the breast. Cell 61:1121-1135, 1990
95. Matsui Y, Halter SA, Holt JT, Hogan BLM, Coffey RJ, Development of mammary hyperplasia and neoplasia in MMTV-TGFa transgenic mice. Cell 61:1147-1155, 1990
96. Massagu , J: Epidermal growth factor-like transforming growth factor II: interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J Biol Client 258:13614-13620, 1983
97. Green MR, Basketter DA, Coudman JR, Ros D, A: Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth. Dev Biol 100:506-512, 1983
98. Chang EH, Furth M, Scolnick EM, Lowy D, R: Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297:478-481, 1982
99. Laçai JE, Tronick S, R: The ras oncogene. In: Reddy EP, Skalka AM, Curran T (eds.). The Oncogene Handbook. Elsevier, Amsterdam, p 257-304, 1988
100. Vassar R, Hutton E, Fuchs , E: Transgenic overexpression of transforming growth factor a bypasses the need for c-H-ras mutations in mouse skin tumorigenesis. Mol Cell Biol 12:4643-4653, 1992
101. Fu X-Y, Zhang J-, J: Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74:1135-1140, 1993
102. Land H, Parada LF, Weinberg R, A: Transgenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:546-602, 1983
103. Eliyahu D, Mechaloritz D, Eliyahu S, Pinhasi-Kimhi O, Oren , M: Wild-type p53 can inhibit oncogene mediated focus formation. Proc Nail Acai Sci USA 86:8763-8769, 1986
104. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson S, S: Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis-interaction of c-myc and transforming growth factor-alpha in hepatic oncogenesis. Cancer Res 53:1719-1723, 1993
105. Kim SH, Roth KA, Moser A, Grodon J, I: Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia.J Cell Biol 123:877-893, 1993
106. Brisette JL, Missero C, Yuspa SH, Dotto G, P: Different levels of v-Ha-ras p21 expression in primary keratinocytes transformed with Harvey Sarcoma virus correlate with benign versus malignant behavior. Mol Carcinog 7:21-25, 1993
107. Donehower LA, Harvey M, Slagel BL, McArthur MJ, Montgomery CA, Jr, Butel JS, Bradley , A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221, 1992
108. Cutry AF, Kinniburgh AJ, Twardzik DR, Wenner C, E: Transforming growth factor alpha (TGFa) induction of c-fos and c-myc expression in C3H 10T1/2 cells. Biocliem Biophys Res Commun 152:216-222, 1988
109. Sagar SM, Edwards RH, Shar F, R: Epidermal growth factor and transforming growth factor a induce c-fos gene expression in retinal muller cells m vii'O.J Kcuro Res 29:549-559, 1991
110. Jhappan C, Takayama H, Dickson RB, Melino , G: Transgenic mice provide genetic evidence that transforming growth fact a promotes skin tumorigen-esis via H-ras dependent and H-ras independent pathways. Cell Crou-th and Diff 5:385-394, 1994
111. Shuai K, Stark GR, Kerr IM, Daraell Jr, J, E: A single phosphotyrosine residue of Stat p91 required for gene activation by interferon-y. Science 261:1722-1746, 1993
112. Lu B, Rothnagel JA, Longley MA, Tsai SY, Roop D, R: Differentiation specific expression of human keratin 1 is mediated by a composite AP-1 steroid hormone element. J Biol Client 209:7443-7449, 1996
113. Harper JR, Roop DR, Yuspa S, H: Transfection of EJ ras into keratinocytes derived from carcinogen-induced mouse papillomas causes malignant progression. Mol Cell Biol 6:3144-3149, 1986
114. Hollstein M, Sidransky D, Vogelstein B, Harris CG: p53 mutations in human cancers. Science 253:49-51, 1991
115. Greenblatt MS, Bennett WP, Hollstein M, Harris C, C: Mutation in the p53 tumor suppressor gene: links to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878. 1994
116. Malkin D, Li FP, Stong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischof FZ, Tainsky MA, Friend S, H: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250:1233-1238, 1990
117. Hinds PW, Finlay CA, Levine A, J: A point mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739-1093, 1989
118. Harper JW, Adami GR, Wei NW, Keyomarsi H, Elledge S, J: The p21 Cdk-interacting, protein CIP1 is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75:805-816, 1993
119. El-Deiry WS, Tokino T, Velculescu VE, levy DB, Parson R, Trent JM, Lin D, Mercer EW, Kinzler KW, Vogelstein , B: WAF1 a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
120. Hartwell , L: Defects in a cell cycle checkpoint maybe responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992
121. Perry ME, Levine A, J: Tumor suppressor p53 and the cell cycle. Cttrr Opin Genet Dcv 3:50-54, 1993
122. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992
123. Wemess BA, Levine AJ, Howley P, M: The E6 proteins encoded by human papillomavirus types 16 and 18 can complex p53 in vitro. Science 248:76-79, 1990
124. Dittmeyer D, Pato S, Zambetti G, Chu S, Tersky AK, More M, Finlay L, Levine A, J: Gain of function p53 mutants. Nat Genet 4:42-46, 1993
125. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten , J: A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Prof Kttl Acad Sci USA 8:10124-10128. 1991
126. Pierceall WE, Mukhopadhyay T, Goldberg LH, Ananthaswamy H, N: Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog 4:445-449, 1991
127. Gusterson B A, Anbazhagan R, Warren W, Midgely C, Lane DP, O'Hare M, Stamps A, Carter R, Jayatilake , H: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6:1785-1789, 1991
128. Sim CS, Slater S, McKee P, N: Mutant p53 expression in solar keratosis: an immunohistochemical study. J Cutaa Path 19:302-308, 1992
129. Ziegler A, Jonason AS, Leffell DJ, Simon JH, Sharma HW, Kimmelman J, Rammington L, Jacks T, Brash D, E: Sunburn and p53 in the onset of skin cancer. Nature 372:773-776, 1994
130. Parada LF, Land H, Weinberg RA. Wolf D, Rotter , V: Cooperation between the gene encoding p53 tumor antigen and ras in cellular transformation. Nature 312:649-651, 1984
131. Eliyahu D, Raz A, Gross P, Givol D, Oren , M: Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature 312:646-649, 1984
132. Chen PL, Chen Y, Bookstein R, Lee W, H: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580, 1990
133. Wyllie FS, Lemolne WR, Barton CN, Dawson T, Bond J, Wynford-Thomas , D: Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Cminog 7:83-88, 1993
134. Lu X, Park SH, Thompson TC, Lane DP: ras induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70:153-161, 1992
135. Kemp CJ, Donehower LA, Bradley A, Balmain , A: Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813-822, 1993
136. sH oncogene. Cancer Res 54:5584-5592, 1994
137. Strasser A, Harris AW, Jacks T, Cory , S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339, 1994
138. Pietenpol JA, Papadopoulos N, Markowitz S, Willson HKV, Kinzler KW, Vogelstein , B: Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 54:3714-3717, 1994
139. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, Smith J, R: Evidence for a 53-independent pathway for upregulation of SDIl/ClPI/WAFI/p21 RNA in human cells. AM Carcinog 11:59-65, 1994
140. Greenhalgh DA, Rothnagel JA, Wang XJ, Dominey AM, Roop D, R: Transgenic models for inherited and acquired skin disorders. In: Watt F, Lane B, Leigh I (eds.). Tlie Keratinocyte Handbook. Cambridge University Press, 1994, pp 475-484
141. Greenhalgh DA, Wang XJ, Dominey AM, Rothnagel JA, Roop D, R: Transgenic models for skin carcinogenesis. In: Mukhtar H (ed.). Skin Cancer Mechanisms and Human Relevance. CRC Dermatology Series, CRC, 1994, pp 317-330